Veni, vidi, vici

MEDTRONIC 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Medtronic plc - MDT

Retrieved on: 
Saturday, November 5, 2022
Legal, Professional Services, Company, LLC, Growth, Trustee, Special warfare combatant-craft crewmen, Welfare, NYSE, Veni, vidi, vici, District, New, KSF, Commercial, District court, Local, Court, News, Insurance, Medtronic

This action is pending in the United States District Court for the District of Minnesota.

Key Points: 
  • This action is pending in the United States District Court for the District of Minnesota.
  • Medtronic and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nations premier boutique securities litigation law firms.
  • KSF has offices in New York, California, Louisiana and New Jersey.

MEDTRONIC SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Medtronic plc - MDT

Retrieved on: 
Wednesday, November 2, 2022
Growth, KSF, District court, News, GLOBE, LLC, NYSE, Commercial, District, Welfare, Court, New, Company, Veni, vidi, vici, Local, Trustee, Medtronic

This action is pending in the United States District Court for the District of Minnesota.

Key Points: 
  • This action is pending in the United States District Court for the District of Minnesota.
  • If you wish to serve as a lead plaintiff in this class action, you must petition the Court by November 7, 2022.
  • Medtronic and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nations premier boutique securities litigation law firms.

Panish | Shea | Boyle | Ravipudi LLP Obtains $8 Million Settlement for Parents of Andrés Guardado, Teen Fatally Shot by Los Angeles County Sheriff Deputy

Retrieved on: 
Wednesday, November 2, 2022
Legal, Professional Services, Los Angeles County Board of Supervisors, Superior court, California superior courts, Heart, Publication, Child, Catastrophic injury, Policy, LLP, Family, Risk, Department, Employment, County, Woman, Death, Gun, FBI, Veni, vidi, vici, Parent, Private investigator

Attorneys for the parents of 18-year-old Andrs Guardado, who was fatally shot multiple times by Los Angeles County Sheriff's Department Deputy Miguel Vega, have obtained an $8,000,000 settlement against the County of Los Angeles for the wrongful death of their son.

Key Points: 
  • Attorneys for the parents of 18-year-old Andrs Guardado, who was fatally shot multiple times by Los Angeles County Sheriff's Department Deputy Miguel Vega, have obtained an $8,000,000 settlement against the County of Los Angeles for the wrongful death of their son.
  • The settlement was approved today by the Los Angeles County Board of Supervisors.
  • Plaintiffs Elisa and Cristobal Guardado are represented in the matter by attorneys Adam Shea, Nicholas Yoka, Spencer Lucas, and Ryan Casey of Panish | Shea | Boyle | Ravipudi LLP.
  • On June 18, 2020, Los Angeles County Sheriff's Department Deputy Miguel Vega and his partner Deputy Chris Hernandez pulled up to Andrs' place of employment in Gardena, California.

MEDTRONIC HOLDINGS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Medtronic plc - MDT

Retrieved on: 
Wednesday, October 26, 2022
Company, Commercial, District court, Growth, Local, Veni, vidi, vici, Trustee, Lawyer, News, New, Welfare, GLOBE, LLC, Lists of schools in England, FREE, District, NYSE, Security (finance), Medtronic

This action is pending in the United States District Court for the District of Minnesota.

Key Points: 
  • This action is pending in the United States District Court for the District of Minnesota.
  • Medtronic investors should visit us at https://claimsfiler.com/cases/nyse-mdt-4/ or call toll-free (844) 367-9658.
  • Medtronic and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements.

Research supported by Royal Commission for AlUla provides new insights into huge, ancient animal traps known as 'kites'

Retrieved on: 
Monday, October 24, 2022
Work, Socioeconomics, Development, Hunting, Animal, French National Centre for Scientific Research, Education, Bronze Age, Indira Gandhi National Centre for the Arts, Late, Research, RCU, Vision 2030, History, University, Arabian Archaeology and Epigraphy, Archaeological science, Agence nationale de la recherche, Veni, vidi, vici, Economic development, Scientific method, Press release, Agency, Nature, Late Neolithic, Domestication, Tourism, Epigraphy, Neolithic, Diffusion, Kingdom, Aerial archaeology, Chronology, University of Western Australia, CNRS, Toy, Archaeology, Harrat al-Sham, Al-'Ula, KSA

Dr Remy Crassard, a leading expert on desert kites, notes that they are some of the largest ancient structures of their era.

Key Points: 
  • Dr Remy Crassard, a leading expert on desert kites, notes that they are some of the largest ancient structures of their era.
  • Kites may have led to hunting well beyond subsistence levels, related to "an increase in symbolic behaviour related to food production and social organisation".
  • That hub, the Kingdoms Institute, is currently active as a research organization, with plans to open a physical presence at AlUla by 2030.
  • The RCU-sponsored research in and around AlUla is adding to the knowledge base that will inform the Kingdoms Institute.

Interim Results of MATCH Study Demonstrate Improved Decision Making and Clinical Outcomes When Using Mind.Px™ to Determine Biologic Drug Class for Psoriasis Patients

Retrieved on: 
Thursday, October 20, 2022
CAP, Physician, CA, Psoriasis, ISO, PX, CLIA, Population, Conference, Machine learning, Patient, Precision medicine, Certification, MATCH, Decision-making, Doctor of Philosophy, MD, CEO, Health, United, GLOBE, Comorbidity, Veni, vidi, vici, Biomarker, Poster, Medical device, Pharmaceutical industry, Medical imaging

These data validate the willingness of physicians to incorporate Mind.Px test results into their biologic decision making for psoriasis patients as well as demonstrate improved patient outcomes when the test reports were followed.

Key Points: 
  • These data validate the willingness of physicians to incorporate Mind.Px test results into their biologic decision making for psoriasis patients as well as demonstrate improved patient outcomes when the test reports were followed.
  • [ii] Furthermore, successful patient responses to currently available biologic treatments are roughly 52 percent [iii] , leading to trial-and-error patient treatments and increased healthcare costs.
  • Mind.Px is a predictive test used to improve management of psoriasis patients and allows physicians to prescribe biologic drugs with >92 percent positive predictive value.
  • This is a key milestone in demonstrating the clinical utility of the test and, ultimately, incorporation into clinical practice.

MEDTRONIC SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Medtronic plc - MDT

Retrieved on: 
Wednesday, October 19, 2022
News, Local, Growth, LLC, NYSE, District, Commercial, Court, KSF, New, Company, Welfare, District court, Lists of schools in England, GLOBE, Trustee, Veni, vidi, vici, Online gambling, Medtronic

This action is pending in the United States District Court for the District of Minnesota.

Key Points: 
  • This action is pending in the United States District Court for the District of Minnesota.
  • If you wish to serve as a lead plaintiff in this class action, you must petition the Court by November 7, 2022.
  • Medtronic and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nations premier boutique securities litigation law firms.

Minnesota Experiencing Increase in Illicit Fentanyl Exposure

Retrieved on: 
Thursday, October 20, 2022
Pharmaceutical, Health, Mental Health, Medical Supplies, Drug overdose, Doctor of Pharmacy, CDC, Education, JAMA Network Open, Drug Enforcement Administration, DEA, Urine, Multimedia, Medical statistics, UDT, Center, National Center for Health Statistics, CPE, National Center for Health Research, Awareness, Illegal drug trade, Fentanyl, Decision-making, Chronic pain, Lists of diseases, Death, Speech disorder, Veni, vidi, vici, Public health, Pharmaceutical industry, Drug

Millennium Health announced today that illicit fentanyl positivity in Minnesota increased by 400% in patient samples from substance use disorder treatment practices tested during the first half of 2022 compared to 2019.

Key Points: 
  • Millennium Health announced today that illicit fentanyl positivity in Minnesota increased by 400% in patient samples from substance use disorder treatment practices tested during the first half of 2022 compared to 2019.
  • View the full release here: https://www.businesswire.com/news/home/20221020005373/en/
    Millennium Health announced today that illicit fentanyl positivity in Minnesota increased by 400% in patient samples from substance use disorder treatment practices tested during the first half of 2022 compared to 2019.
  • The company released its analysis of urine drug test (UDT) results to help raise community awareness and education.
  • (Graphic: Business Wire)
    A dramatic increase in drug overdose deaths is being reported across the U.S.

Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market

Retrieved on: 
Monday, October 17, 2022
LinkedIn, Congress, Australian Securities Exchange, Head, ICI, Lactic acid, Neoplasm, GE Healthcare, Thomas Edison, TGA, Association, Advertising, Cancer, Carbonic anhydrase, NYSE, Regulation of tobacco by the U.S. Food and Drug Administration, HIV disease progression rates, Company, Marketing, Industry, Nuclear medicine, Diversified Pharmaceutical Services, European Association for the Study of the Liver, Disclosure, FDA, Risk, Review, EANM, Research, Multimedia, Immunotherapy, Degenerative disease, Gallium, Veni, vidi, vici, PD-1, Ecosystem, Oxygen, View, ASX, Patient, European Association of Nuclear Medicine, Partnership, Food, TLX, United Kingdom, PET, Forward-looking statement, JAMA Network Open, Medical imaging, Pharmaceutical industry, Animal, Media, Telix

TLX250-CDx and [18F]-FLac complement GE Healthcare Pharmaceutical Diagnostics' pipeline of investigational non-invasive [18F]-CD8 and[18F]-Granzyme-B imaging tracers for use by pharmaceutical companies in clinical trials, with the potential to predict and monitor response to immunotherapy.

Key Points: 
  • TLX250-CDx and [18F]-FLac complement GE Healthcare Pharmaceutical Diagnostics' pipeline of investigational non-invasive [18F]-CD8 and[18F]-Granzyme-B imaging tracers for use by pharmaceutical companies in clinical trials, with the potential to predict and monitor response to immunotherapy.
  • Sanka Thiru, Global Business Leader, Immuno-Oncology, at GE Healthcare's Pharmaceutical Diagnostics business, said: "This partnership expands our pharmaceutical services offering, including our toolbox of investigational PET imaging diagnostics.
  • Telix and GE Healthcare will explore validation of [18F]-FLac for use in GE Healthcare's FASTlab, an automated PET radiochemistry synthesiser, widely used for onsite production of FDG6 and other PET tracers.
  • The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates all rights reserved.

Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market

Retrieved on: 
Monday, October 17, 2022
LinkedIn, Congress, Australian Securities Exchange, Head, ICI, Lactic acid, Neoplasm, GE Healthcare, Thomas Edison, TGA, Association, Advertising, Cancer, Carbonic anhydrase, NYSE, Regulation of tobacco by the U.S. Food and Drug Administration, HIV disease progression rates, Company, Marketing, Industry, Nuclear medicine, Diversified Pharmaceutical Services, European Association for the Study of the Liver, Disclosure, FDA, Risk, Review, EANM, Research, Immunotherapy, Degenerative disease, Gallium, Veni, vidi, vici, PD-1, Ecosystem, Oxygen, ASX, Patient, European Association of Nuclear Medicine, Partnership, Food, TLX, United Kingdom, PET, Forward-looking statement, JAMA Network Open, Medical imaging, Pharmaceutical industry, Animal, Media, Telix

Sanka Thiru, Global Business Leader, Immuno-Oncology, at GE Healthcare's Pharmaceutical Diagnostics business, said: "This partnership expands our pharmaceutical services offering, including our toolbox of investigational PET imaging diagnostics.

Key Points: 
  • Sanka Thiru, Global Business Leader, Immuno-Oncology, at GE Healthcare's Pharmaceutical Diagnostics business, said: "This partnership expands our pharmaceutical services offering, including our toolbox of investigational PET imaging diagnostics.
  • Telix and GE Healthcare will explore validation of [18F]-FLac for use in GE Healthcare's FASTlab, an automated PET radiochemistry synthesiser, widely used for onsite production of FDG6 and other PET tracers.
  • The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates all rights reserved.
  • CONTACT: Telix Investor Relations: Ms. Kyahn Williamson, Telix Pharmaceuticals Limited, SVP Corporate Communications and Investor Relations, Email: [email protected] ; GE Healthcare Media Contact: Debbie Leven / [email protected] , +44 7785 456999